Skip to content

A Performance Study of (Opportunistic) Salpingectomy

A Performance Study of (Opportunistic) Salpingectomy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05646680
Acronym
QOS
Enrollment
115
Registered
2022-12-12
Start date
2022-12-09
Completion date
2025-04-25
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adnexal Lesion, Ovarian Cancer

Keywords

salpingectomy

Brief summary

The goal of this clinical trial is to test the quality of the performance of opportunistic salpingectomies in women scheduled for adnexectomy. The main questions it aims to answer are: * How many salpingectomies are incomplete? * Are there any factors related to incomplete resection? Could the investigators develop a instruction video to optimize the surgical technique? Participants planned for uni-or bilateral adnexectomy (removal of ovary and salpinx) will have their adnexectomy in two steps in the same surgical episode: first the salpingectomy (removal of the salpinx), then the oophorectomy (the removal of the ovary).

Detailed description

Rationale: Salpingectomy in post-reproductive women could reduce the risk of developing ovarian cancer. In women at high risk for ovarian cancer (because of genetic mutations) a risk reducing salpingectomy with delayed ovariectomy could be an advantage. It is considered that salpingectomy does not cause premature menopausal symptoms. Prospective randomized trials are being performed to estimate the true risk reducing effect of salpingectomy on ovarian cancer. Those studies are based on a complete bilateral salpingectomy. Objective: The QOS study investigates the quality of performance of opportunistic salpingectomy and the risk factors associated with reminiscing fimbrial tissue after salpingectomy. Study design: Multicenter interventional trial Study population: Patients planned for unilateral or bilateral adnexectomy (removal of ovary and salpinx) will be counselled to participate. Intervention: The gynecologist will perform the adnexectomy in two steps in the same surgical episode: first the salpingectomy (removal of the salpinx), then the oophorectomy (the removal of the ovary). The pathologist investigates for pathology and describes if fimbrial tissue (the last part of the salpinx adjacent to the ovary) has been left behind on the ovarian surface microscopically and macroscopically. Main study parameters/endpoints: The primary outcome is the percentage of incomplete salpingectomies. Secondary outcome is the detection of factors related to incomplete resection of the salpinx. If necessary a guideline/instruction video could be developed to optimize the surgical technique. A total of 200 specimens are to be included to answer the primary endpoint.

Interventions

PROCEDUREtwo step adnexectomy

instead of standard resection of salpinx and ovary, they are now separately excised

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients scheduled for uni- or bilateral adnexectomy. (may be in combination with hysterectomy) AND \* competent to act on itself * dutch speaking * signed informed consent

Exclusion criteria

\* Endometrial cancer or invasive cervical cancer * radiotherapy in the pelvis in the medical history * (partial) salpingectomy * Pelvic Inflammatory Disease * Adnexectomy for gender transformation surgery if wish to preserve the ovarian tissue. * Surgery in two steps is not safe to perform * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Percentage of incomplete salpingectomies10 daysThe rate of ovarian samples on which residual fimbrial or fallopian tube tissue has been left behind.(macroscopically and microscopically)

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026